UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14a
(RULE 14a-101)
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934
|
Filed by the Registrant ⌧
|
|
|
Filed by a Party other than the Registrant □
|
|
|
Check the appropriate box:
|
|
| ☐ |
Preliminary proxy statement
|
| ☐ |
Confidential, for use of the Commission Only (as permitted by Rule 14a-6(e)(2))
|
| ☐ |
Definitive Proxy Statement
|
| ☒ |
Definitive Additional Materials
|
| ☐ |
Soliciting Material Pursuant to §240.14a-12
|
|
CATALYST BIOSCIENCES, INC.
|
||
|
(Name of Registrant as Specified in its Charter)
|
||
|
(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)
|
||
|
Payment of Filing Fee (Check the appropriate box):
|
||
| ☒ |
No fee required.
|
|
| ☐ |
Fee paid previously with preliminary materials.
|
|
| ☐ |
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11
|
|
On July 29, 2022, Catalyst Biosciences, Inc. (the “Company”) distributed two letters to stockholders in connection with the Company’s 2022 annual meeting of stockholders. Copies of the letters can be found below.
